Vaderis Therapeutics’ VAD044 Receives FDA Fast Track Designation for Treating Hereditary Hemorrhagic Telangiectasia
Vaderis Therapeutics' VAD044 Receives FDA Fast Track Designation for Treating Hereditary Hemorrhagic Telangiectasia Vaderis Therapeutics AG, a clinical-stage biotechnology company focusing on treatmen ...